Evidence map›Paper›PMID 41163948›Full record

ArticleTherapeutic advances in gastroenterology2025

Gastrointestinal bacterial infections precede disease activation and treatment intensification in patients with inflammatory bowel disease.

Merit Kase, Krista Johanna Vitikainen, Clas-Göran Af Björkesten, Veli-Jukka Anttila, Leo Meriranta, Perttu Arkkila, Pauliina Molander

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Microbiota-derived indole limitsScience advances · 2026
    Article
  2. Deciphering the Implications ofPathogens (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Merit KaseDepartment of Internal Medicine and Rehabilitation, Helsinki University Hospital and University of Helsinki, P.O. Box 340 (Haartmaninkatu 4), Helsinki FI-00290, Finland.ORCID https://orcid.org/0000-0002-2298-857X
Krista Johanna VitikainenDepartment of Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0009-0006-1609-383X
Clas-Göran Af BjörkestenAbdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Veli-Jukka AnttilaDepartment of Infectious Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Leo MerirantaDepartment of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Perttu ArkkilaAbdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Pauliina MolanderAbdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-9494-3573

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with inflammatory bowel disease (IBD) are at heightened risk of infection for several reasons. Objectives: To evaluate the factors predisposing IBD patients to gastrointestinal (GI) infections, the elements influencing the severity of these infections and the likelihood of hospitalization, and the impact of GI bacterial infections on the progression of IBD. Design: Retrospective, single-center, case-control study of IBD patients with GI infection and matched controls. Methods: Patients with ulcerative colitis (UC) or Crohn's disease who tested positive for Results: Of the 5194 IBD patients in the IBD registry, 123 patients had a confirmed GI infection, the majority having UC ( Conclusion: Our study indicates that IBD patients diagnosed with GI infections may be at elevated risk of experiencing an IBD flare within 1-6 months post-infection, often necessitating the intensification of their pharmacological treatment.

Indexed as

CampylobacterCrohn’s diseasegastrointestinal infectionSalmonellaulcerative colitisYersinia

Identifiers

PMID41163948
PMCPMC12559649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.